Perspective Therapeutics (CATX) Other Non-Current Liabilities (2011 - 2026)
Perspective Therapeutics (CATX) reported Other Non-Current Liabilities of $437000.0 for Q1 2026, up 201.38% on a YoY basis from $145000.0 in Q1 2025, and up 13.21% sequentially from $386000.0 in Q4 2025.
Perspective Therapeutics (CATX) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Perspective Therapeutics (CATX) has 16 years of Other Non-Current Liabilities data on file, last reported at $437000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 201.38% year-over-year to $437000.0; the trailing twelve-month figure through Mar 2026 stood at $437000.0 (up 201.38% YoY), and the FY2025 full-year result was $386000.0, up 601.82% from the prior year.
- Other Non-Current Liabilities advanced to $437000.0 in Q1 2026, from $386000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $668000.0 in Q3 2023 to a low of $19000.0 in Q2 2024.
- A 5-year average of $418133.3 and a median of $437000.0 in 2026 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities sank 97.12% in 2024 and surged 1394.74% in 2025, its largest moves.
- Tracing CATX's Other Non-Current Liabilities over 5 years: stood at $657000.0 in 2022, then increased by 1.67% to $668000.0 in 2023, then slumped by 91.77% to $55000.0 in 2024, then jumped by 601.82% to $386000.0 in 2025, then gained by 13.21% to $437000.0 in 2026.
- Business Quant data shows CATX's Other Non-Current Liabilities at $437000.0 in Q1 2026, $386000.0 in Q4 2025, and $342000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 437,000.00 |
| Dec 31, 2025 | 386,000.00 |
| Sep 30, 2025 | 342,000.00 |
| Jun 30, 2025 | 284,000.00 |
| Mar 31, 2025 | 145,000.00 |
| Dec 31, 2024 | 55,000.00 |
| Sep 30, 2024 | 33,000.00 |
| Jun 30, 2024 | 19,000.00 |
| Sep 30, 2023 | 668,000.00 |
| Jun 30, 2023 | 659,000.00 |
| Mar 31, 2023 | 666,000.00 |
| Dec 31, 2022 | 657,000.00 |
| Sep 30, 2022 | 649,000.00 |
| Jun 30, 2022 | 640,000.00 |
| Mar 31, 2022 | 632,000.00 |
| Dec 31, 2021 | 624,000.00 |
| Sep 30, 2021 | 616,000.00 |
| Jun 30, 2021 | 608,000.00 |
| Mar 31, 2021 | 600,000.00 |
| Dec 31, 2020 | 593,000.00 |